RSV 진단 시장 : 세계 예측(2026-2032년)

The RSV Diagnostics Market is projected to grow by USD 13.39 billion at a CAGR of 10.89% by 2032.

RSV Diagnostics Executive Summary

Respiratory syncytial virus (RSV) diagnostics have become a critical component of respiratory infection management as RSV continues to cause substantial illness across infants, older adults, and immunocompromised populations. RSV is recognized by public health agencies as a leading cause of bronchiolitis and pneumonia in young children and a clinically important respiratory pathogen among adults aged 60 years and older and people with chronic cardiopulmonary disease. The diagnostic landscape is shifting from symptom-based assessment toward laboratory-confirmed detection using molecular assays, rapid antigen tests, multiplex respiratory panels, and point-of-care platforms. This shift is being reinforced by expanded RSV immunization strategies, stronger hospital infection-control protocols, and growing demand for timely differentiation between RSV, influenza, SARS-CoV-2, and other respiratory pathogens. Accurate RSV testing supports clinical triage, antimicrobial stewardship, outbreak monitoring, and targeted protection of high-risk groups. As health systems prioritize faster turnaround, decentralized testing, quality-assured specimen collection, and syndromic respiratory diagnostics, RSV diagnostics are increasingly positioned as a core tool in seasonal preparedness and evidence-based respiratory care.

Transformative Shifts in the RSV Diagnostics Landscape

The RSV diagnostics landscape is being reshaped by several transformative shifts. Molecular testing has gained prominence because nucleic acid amplification methods provide high analytical sensitivity and can detect low viral loads, particularly in early infection, hospitalized patients, and vulnerable populations. At the same time, rapid antigen tests remain important where speed, affordability, and operational simplicity are prioritized, especially in urgent care, pediatric settings, emergency departments, and resource-limited environments, while their performance is generally stronger in young children with higher viral loads than in adults. Multiplex respiratory panels are also changing clinical workflows by enabling simultaneous detection of RSV, influenza, SARS-CoV-2, and additional viral or bacterial pathogens from a single specimen. This is particularly valuable during overlapping respiratory seasons, when clinical symptoms are difficult to distinguish. Point-of-care RSV testing is expanding the role of diagnostics beyond central laboratories by supporting faster decisions in emergency departments, outpatient clinics, long-term care facilities, and community health programs. These changes are supported by improved nasopharyngeal and nasal sample collection practices, laboratory automation, digital reporting, antimicrobial stewardship programs, and surveillance networks that connect diagnostic results with public health intelligence.

Cumulative Impact of Artificial Intelligence on RSV Diagnostics

Artificial intelligence is adding a new layer of value to RSV diagnostics by improving workflow efficiency, clinical interpretation, and epidemiological intelligence. In laboratory environments, AI-enabled automation can help optimize sample routing, reduce manual review burden, identify quality-control anomalies, support inventory planning during seasonal respiratory surges, and accelerate result validation. In clinical settings, machine learning models can combine diagnostic results with age, symptoms, comorbidities, vaccination or prophylaxis status, oxygen requirement, care setting, and local respiratory virus activity to support risk stratification and care prioritization. AI is also strengthening respiratory surveillance by detecting trends in test positivity, geographic clustering, seasonality patterns, and potential institutional outbreaks across connected datasets. For multiplex testing, algorithmic interpretation can assist clinicians in understanding co-detections and differentiating likely clinically relevant findings from incidental results. However, responsible adoption requires validated datasets, transparent model performance, privacy-preserving data governance, cybersecurity safeguards, human oversight, and continuous monitoring for bias across age groups, geographies, socioeconomic contexts, and care settings.

Key Regional Insights for RSV Diagnostics

In Asia-Pacific, RSV diagnostics are influenced by dense urban populations, diverse healthcare access levels, tropical and temperate seasonality, and strong demand for scalable respiratory testing in countries with high pediatric disease burdens. The region is seeing increasing use of molecular diagnostics in tertiary care while rapid testing remains relevant for decentralized and high-volume clinical environments, particularly where laboratory access varies between metropolitan and rural areas. Europe benefits from coordinated respiratory virus monitoring, well-established laboratory quality systems, and growing integration of RSV testing into syndromic respiratory panels, particularly during winter respiratory seasons. European surveillance frameworks also support laboratory-confirmed reporting that helps clinicians and public health authorities track RSV circulation alongside influenza and SARS-CoV-2. North America demonstrates mature adoption of molecular and multiplex respiratory testing, supported by established laboratory networks, seasonal surveillance, hospital infection-control programs, electronic reporting, and expanding attention to RSV in older adults. Latin America is advancing RSV detection through public health surveillance, pediatric respiratory programs, sentinel monitoring, and broader access to rapid and molecular tools, though infrastructure variability continues to shape testing availability across urban, rural, and remote settings. Across Africa, RSV remains a major pediatric respiratory health concern, and diagnostic development is closely tied to laboratory capacity building, sentinel surveillance, affordable rapid testing, workforce training, and access to quality-assured molecular platforms in referral centers. In the Middle East, RSV diagnostics are supported by healthcare modernization, hospital-based molecular testing, digital health investment, and preparedness for respiratory outbreaks in high-mobility populations, including settings affected by travel, pilgrimage, and cross-border healthcare utilization.

Key Group Insights for RSV Diagnostics

NATO member countries, many of which overlap with high-income healthcare systems, are emphasizing respiratory readiness, laboratory resilience, secure data exchange, and interoperable surveillance capabilities that can support rapid identification of RSV trends alongside influenza, SARS-CoV-2, and other respiratory pathogens. G7 countries generally demonstrate advanced adoption of molecular diagnostics, syndromic panels, electronic reporting, laboratory accreditation systems, and evidence-based respiratory infection management, making RSV testing an increasingly routine component of seasonal care pathways for infants, older adults, and medically vulnerable patients. BRICS countries show diverse diagnostic maturity, with large population bases driving demand for scalable RSV testing, domestic laboratory capacity, public-sector surveillance, and expanded access across mixed public and private healthcare systems. Within the European Union, harmonized surveillance priorities, regulatory alignment, cross-border disease monitoring, and established laboratory networks support broader use of validated RSV assays and multiplex respiratory panels, while standardized respiratory virus reporting improves comparability across member states. Across ASEAN, RSV diagnostics are shaped by tropical and subtropical seasonality, high pediatric care demand, and the need for cost-effective tools that can function across urban hospitals, district facilities, and community clinics. GCC countries are strengthening respiratory diagnostics through healthcare infrastructure investment, centralized laboratories, digital health systems, infection-prevention programs, and preparedness strategies for seasonal and travel-associated respiratory infections.

Key Country Insights for RSV Diagnostics

China is advancing respiratory pathogen detection through expanded molecular testing capacity, hospital networks, respiratory surveillance experience, and growing adoption of multiplex platforms that help distinguish RSV from influenza, SARS-CoV-2, and other viruses. The United States has expanded clinical attention to RSV diagnostics through hospital-based molecular testing, multiplex respiratory panels, surveillance reporting, immunization-related awareness, and heightened focus on infants, older adults, and long-term care settings. Japan and South Korea demonstrate advanced diagnostic capabilities, strong laboratory quality systems, high digital health readiness, and established respiratory virus monitoring that support timely RSV detection and clinical decision-making. India faces high pediatric respiratory disease demand, making affordable rapid diagnostics, referral laboratory testing, quality-assured molecular capacity, and scalable surveillance important for RSV management across public and private care settings. Germany, France, Italy, and Spain have strong laboratory infrastructures supporting molecular RSV testing, multiplex diagnostics, and winter respiratory infection management across hospital and outpatient pathways, with surveillance systems that increasingly track RSV alongside influenza and SARS-CoV-2. The United Kingdom uses integrated respiratory surveillance and laboratory diagnostics to track RSV seasonality, guide clinical awareness, and support prevention strategies for high-risk populations. Australia uses seasonal surveillance, public health reporting, and molecular testing to monitor RSV activity, with diagnostic decisions influenced by regional seasonality and the needs of pediatric and older adult care. Canada integrates RSV testing into seasonal respiratory virus monitoring and uses laboratory-confirmed data to guide public health communication and healthcare planning. Russia's RSV diagnostic activity is shaped by large-scale healthcare geography, varied climates, and the need for surveillance across dispersed populations. Brazil relies on hospital surveillance, pediatric respiratory programs, and laboratory networks to support RSV detection across a geographically diverse healthcare environment, while Mexico continues to build respiratory diagnostic capacity across public and private systems, with RSV testing increasingly relevant in pediatric respiratory care.

Actionable Recommendations for RSV Diagnostics Leaders

Industry leaders should prioritize assay accuracy, operational simplicity, and clinical workflow integration when developing or deploying RSV diagnostics. Molecular platforms should be optimized for rapid turnaround, high throughput, and compatibility with multiplex respiratory panels, while rapid antigen and point-of-care tests should focus on usability, quality control, and performance transparency across age groups, specimen types, and care settings. Diagnostic providers should align product strategies with respiratory season preparedness, emergency department triage, pediatric care pathways, long-term care infection control, immunization program awareness, and public health surveillance requirements. Expanding access requires flexible pricing models, training programs, decentralized testing support, reliable supply chains, specimen collection guidance, and partnerships with laboratories, healthcare systems, and public health agencies. Leaders should also invest in digital connectivity, automated reporting, AI-assisted analytics, and interoperable data systems that transform RSV test results into actionable clinical and epidemiological insights. Regulatory readiness, analytical and clinical validation, post-market performance monitoring, real-world evidence generation, and transparent communication of test limitations will be essential for sustained trust and adoption.

Research Methodology for RSV Diagnostics Analysis

This executive summary is developed using a structured secondary research approach focused on verified public health, clinical, regulatory, and scientific sources. The methodology emphasizes evidence from peer-reviewed literature, national and regional public health agencies, clinical guideline bodies, laboratory standards organizations, respiratory virus surveillance programs, and regulatory communications related to RSV testing and respiratory diagnostics. Insights are synthesized across technology categories, including molecular assays, antigen detection, multiplex respiratory panels, point-of-care testing, laboratory automation, digital reporting systems, and AI-enabled analytics. Regional, group, and country-level analysis considers healthcare infrastructure, surveillance maturity, disease burden relevance, diagnostic accessibility, clinical adoption patterns, laboratory quality systems, and public health reporting practices without using market sizing, market share, or forecasting. Each conclusion is triangulated across multiple source types where possible, with preference given to data-backed, clinically validated, and publicly documented information.

Conclusion

RSV diagnostics are moving from a seasonal support function to a strategic pillar of respiratory infection management. The convergence of molecular testing, rapid point-of-care diagnostics, multiplex respiratory panels, digital connectivity, and AI-enabled analytics is improving the ability of healthcare systems to detect RSV quickly and distinguish it from other respiratory pathogens. Regional differences in infrastructure, surveillance capacity, affordability, seasonality, and clinical practice continue to shape adoption, but the underlying direction is consistent: faster, more accurate, and more accessible RSV testing is becoming essential for protecting infants, older adults, and medically vulnerable populations. Organizations that combine reliable assay performance with workflow efficiency, data integration, responsible AI use, and public health relevance will be best positioned to support modern respiratory care and strengthen respiratory virus preparedness.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. RSV Diagnostics Market, by Product

• 7.1. Introduction
• 7.2. Instruments
  • 7.2.1. Analyzers
  • 7.2.2. PCR Machines
• 7.3. Kits
  • 7.3.1. Saliva Collection Kits
  • 7.3.2. Swab Collection Kits
• 7.4. Reagents
  • 7.4.1. Buffers
  • 7.4.2. Enzymes

8. RSV Diagnostics Market, by Test Type

• 8.1. Introduction
• 8.2. Immunoassay
  • 8.2.1. Chemiluminescence Immunoassay
  • 8.2.2. Enzyme Linked Immunosorbent Assay
  • 8.2.3. Immunofluorescence Assay
• 8.3. Molecular Test
  • 8.3.1. Isothermal Amplification
  • 8.3.2. Next Generation Sequencing
  • 8.3.3. Real Time Polymerase Chain Reaction
• 8.4. Rapid Test
  • 8.4.1. Lateral Flow Assay
  • 8.4.2. Microfluidic Assay

9. RSV Diagnostics Market, by Technology Platform

• 9.1. Introduction
• 9.2. ELISA
• 9.3. Immunofluorescence
• 9.4. PCR

10. RSV Diagnostics Market, by Sample Type

• 10.1. Introduction
• 10.2. Blood
• 10.3. Nasopharyngeal Swab
• 10.4. Saliva

11. RSV Diagnostics Market, by Age Group

• 11.1. Introduction
• 11.2. Adult
• 11.3. Geriatric
• 11.4. Pediatric

12. RSV Diagnostics Market, by End User

• 12.1. Introduction
• 12.2. Academic Institutes
• 12.3. Clinics
• 12.4. Diagnostic Laboratories
• 12.5. Home Care
• 12.6. Hospital Laboratories

13. RSV Diagnostics Market, by Distribution Channel

• 13.1. Introduction
• 13.2. Offline
• 13.3. Online

14. RSV Diagnostics Market, by Region

• 14.1. Asia-Pacific
• 14.2. Europe
• 14.3. North America
• 14.4. Latin America
• 14.5. Africa
• 14.6. Middle East

15. RSV Diagnostics Market, by Group

• 15.1. NATO
• 15.2. G7
• 15.3. BRICS
• 15.4. European Union
• 15.5. ASEAN
• 15.6. GCC

16. RSV Diagnostics Market, by Country

• 16.1. China
• 16.2. United States
• 16.3. Japan
• 16.4. India
• 16.5. Germany
• 16.6. United Kingdom
• 16.7. Australia
• 16.8. France
• 16.9. South Korea
• 16.10. Italy
• 16.11. Canada
• 16.12. Russia
• 16.13. Brazil
• 16.14. Mexico
• 16.15. Spain

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. FPNV Positioning Matrix, 2025
• 17.3. Market Concentration Analysis, 2025
  • 17.3.1. Concentration Ratio (CR)
  • 17.3.2. Herfindahl Hirschman Index (HHI)
• 17.4. Recent Developments & Impact Analysis, 2025
• 17.5. Product Portfolio Analysis, 2025
• 17.6. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Laboratories
• 18.2. Altona Diagnostics GmbH
• 18.3. Atlas Medical GmbH
• 18.4. Becton, Dickinson and Company
• 18.5. Bio-Rad Laboratories, Inc.
• 18.6. bioMerieux SA
• 18.7. BTNX Inc.
• 18.8. CerTest Biotec S.L.
• 18.9. CTK Biotech, Inc.
• 18.10. Danaher Corporation
• 18.11. DiaSorin S.p.A.
• 18.12. F. Hoffmann-La Roche Ltd.
• 18.13. Hologic, Inc.
• 18.14. Merck KGaA
• 18.15. Meridian Bioscience, Inc.
• 18.16. Pro-Lab Diagnostics Inc.
• 18.17. Qiagen GmbH
• 18.18. Quidel Corporation
• 18.19. SA Scientific, Ltd.
• 18.20. Sansure Biotech Inc.
• 18.21. Sentinel Ch S.p.A.
• 18.22. Serion GmbH
• 18.23. Siemens Healthcare GmbH
• 18.24. Thermo Fisher Scientific Inc.
• 18.25. Vela Diagnostics Holding Pte Ltd.
• 18.26. Virax Biolabs Group Limited
• 18.27. Weldon Biotech, Inc.